Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA

📉 D.A. Davidson & CO. decreased its Moderna holdings by 33.7% in Q1, selling 28,170 shares to retain a position worth $2.814 million.

📈 Capital World Investors and Norges Bank established new stakes in the fourth quarter valued at approximately $378 million and $79.7 million respectively.

📊 Moderna trades with a market cap of $24.53 billion, a quick ratio of 2.35, and a negative P/E ratio of -7.59.

💼 President Stephen Hoge sold 53,336 shares for $2.74 million under a pre-arranged Rule 10b5-1 trading plan on June 15th.

📉 Director Abbas Hussain reduced his ownership by 32.01% following the sale of 5,682 shares valued at $264,951.

🏦 Corporate insiders have collectively sold 125,088 shares worth $6.19 million over the last ninety days.

📊 Royal Bank of Canada raised its price target to $45.00 with a 'sector perform' rating on July 7th.

📈 Piper Sandler increased its objective to $77.00 and assigned an 'overweight' rating in late June.

⚖️ Goldman Sachs lifted its target price to $49.00 but maintains a 'neutral' stance as of early May.

📉 Bank of America raised its target to $38.00 while assigning an 'underperform' rating on July 7th.

🎯 The consensus analyst target price stands at $38.27 with an average rating of 'Reduce' across twelve analysts.

💊 Moderna specializes in mRNA therapeutics and vaccines, leveraging synthetic mRNA to produce proteins for disease prevention.

Bullish Signals
  • Capital World Investors initiated a new stake worth approximately $378.3 million in the fourth quarter.
  • Norges Bank purchased a new position valued at roughly $79.7 million during the fourth quarter.
  • Invesco Ltd. increased its Moderna stake by 15.7% in the third quarter, now holding shares worth $212.2 million.
  • Dimensional Fund Advisors LP raised its holdings by 123.2% in the fourth quarter, adding nearly 987,000 shares.
  • Royal Bank of Canada upgraded its price target to $45.00 with a 'sector perform' rating.
  • Piper Sandler increased its price objective to $77.00 and assigned an 'overweight' rating.
  • Moderna maintains strong liquidity with a quick ratio of 2.35 and a current ratio of 2.41.
Risk Factors
  • D.A. Davidson & CO. significantly reduced its holdings by 33.7% in the first quarter.
  • The consensus analyst target price is $38.27, which is below the recent trading price of $61.82.
  • The average analyst rating is 'Reduce' based on data from MarketBeat.com.
  • President Stephen Hoge sold 53,336 shares representing a 3.47% decrease in his personal position.
  • Director Abbas Hussain reduced his ownership by 32.01% following the sale of 5,682 shares.
  • Corporate insiders have sold a total of 125,088 shares valued at $6.19 million in the last ninety days.
  • Goldman Sachs maintains a 'neutral' rating despite raising its price target to $49.00.
  • Bank of America assigned an 'underperform' rating even after lifting its price objective to $38.00.
Full Analysis
D.A. Davidson & CO. reduced its position in Moderna, Inc. (NASDAQ: MRNA) by 33.7% during the first quarter, selling 28,170 shares to hold a remaining stake of 55,397 shares valued at $2.814 million. This filing highlights a mixed institutional landscape where other major funds like Capital World Investors and Norges Bank established new stakes in the fourth quarter, while Dimensional Fund Advisors significantly increased its holdings by over 123%. Moderna's stock currently trades with a market capitalization of $24.53 billion and a negative P/E ratio of -7.59, reflecting its biotechnology sector status. The company maintains strong liquidity metrics with a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Recent insider activity includes President Stephen Hoge selling approximately $2.74 million in shares and Director Abbas Hussain reducing his position by over 32%, though total corporate insider ownership remains at 10.80%. Analyst sentiment regarding MRNA is currently mixed, with a consensus target price of $38.27 from MarketBeat data. While Royal Bank of Canada and Piper Sandler raised their price targets to $45 and $77 respectively with positive or overweight ratings, Goldman Sachs and Bank of America maintain neutral to underperform ratings. The average analyst rating is 'Reduce', indicating a cautious outlook despite the company's established mRNA platform for vaccines and therapeutics.